Related Experiment Video
Updated: Feb 19, 2026
03:19
Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes
Published on: June 28, 2024
809
Folate during antifolate chemotherapy: what we know... and do not know
1Cancer Prevention Program, Fred Hutchinson Cancer Research Center, PO Box 19024, M4-B402 Seattle, Washington 98109-1024, USA. krobien@fhcrc.org
Summary
Optimal folate intake during antifolate chemotherapy is unclear. Higher folate may reduce toxicity but could decrease treatment effectiveness and promote tumor growth, necessitating further research.
Area of Science:
- Oncology
- Nutritional Biochemistry
Background:
- Folate is vital for cell growth; folate-dependent enzymes are chemotherapy targets.
- Antifolate chemotherapy efficacy is influenced by folate metabolism.
- Clinical guidelines for folate intake during antifolate therapy are lacking.
Purpose of the Study:
- To review folate and antifolate metabolism.
- To summarize current knowledge on folate-antifolate interactions.
- To highlight the need for research on optimal folate intake during treatment.
Main Methods:
- Literature review of folate and antifolate metabolism.
- Synthesis of existing research on folate-antifolate interactions in chemotherapy.
Main Results:
- Folate is essential for normal cell function and is a cofactor for enzymes targeted by chemotherapy.
- Higher folate intake may reduce chemotherapy toxicity but raises concerns about reduced efficacy and potential tumor growth.
- The precise balance between folate intake, toxicity, and efficacy in antifolate chemotherapy remains to be fully elucidated.
Conclusions:
- Understanding folate and antifolate metabolism is crucial for optimizing cancer therapy.
- Further research is needed to establish optimal dietary and supplemental folate levels during antifolate chemotherapy.
- Evaluating folate status before, during, and after treatment is recommended for future studies.
More Related Videos
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
16
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
16
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
01:10Drugs that Destabilize Microtubules
4.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.1K
01:27Combined Effects of Drugs: Synergism
7.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.0K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
719
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
719
01:15Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K